Chronic Hepatitis B Vaccine
Hepatitis B
ResearchActive
Key Facts
About Orlance
Orlance is advancing the MACH-1 platform, a needle-free gene gun technology that delivers powdered DNA or RNA vaccines directly into the epidermis, aiming to reduce doses by up to 90% and eliminate cold chain requirements. The company has secured significant non-dilutive funding, primarily from NIH SBIR grants totaling over $16.8M, to progress its pipeline toward Phase 1 trials. With a lead universal flu vaccine at the pre-IND stage, Orlance is preparing for a $12M Series A round in 2026 and is actively seeking development partners to expand its portfolio of vaccine and immunotherapy assets.
View full company profileTherapeutic Areas
Other Hepatitis B Drugs
| Drug | Company | Phase |
|---|---|---|
| Vaxine Hep B Vaccine | Vaxine | Phase 1 |
| BEVAC | Biological E. | Commercial |
| Hepatitis B Virus Program | Ai-Biopharma | Preclinical |
| MDL-001 | Model Medicines | Preclinical |
| AdHBV | Adimmune | Preclinical |